Sort
4,870 grants matching “glp 1”
Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation
$1,015,754Dianna Ammons Johnson · Tavo Biotherapeutics, Inc · R44 · FY2025 · EY
A Bullet Proof vascular graft to prevent dialysis access cannulation injury
$1,015,580Joseph Knight · Innavasc Medical, Inc. · R44 · FY2018 · DK
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
$1,014,729Bradley T. Keller · Accuronix Therapeutics, Inc. · R42 · FY2021 · CA
Apical Access System with Universal Connector for Beating Heart LVAD Implantation
$1,014,469Jorge Hernan Jimenez · Apk Advanced Medical Technologies, Inc. · R44 · FY2014 · HL
Development of IN-003PI as passive immunization against human metapneumovirus infection
$1,013,468Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage
$1,012,644Maja Nowakowski · Biomedica Management Corporation · R44 · FY2013 · HL
Neuroprotective role of GLP-1 receptor agonists
$1,010,237Nigel H. Greig · National Institute On Aging · ZIA · FY2015 · AG
Antibody immunotherapeutics for biodefense against Lassa virus
$1,010,001Robert F Garry · Tulane University Of Louisiana · R01 · FY2015 · AI
Novel Vaccine Technology for Chikungunya
$1,007,233Scott C Weaver · University Of Texas Med Br Galveston · R01 · FY2011 · AI
Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy
$1,007,156Srinivas Sridhar · Theranano, Llc · R42 · FY2019 · CA
Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children
$1,007,115Will Clifton · Polyvascular Corporation · R44 · FY2021 · HL
Development of Novel Therapeutic Agents for Norovirus Infection
$1,005,959Kyeong-Ok Chang · Kansas State University · U01 · FY2011 · AI
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
$1,005,952Justin Blaine Schaal · University Of Southern California · R01 · FY2023 · AI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
$1,004,563Jay L Rothstein · Immunext, Inc. · R44 · FY2019 · AI
AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy
$1,004,473Ariel Weinberger · Autonomous Therapeutics, Inc. · R44 · FY2025 · AI
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
$1,002,483Valerie Humblet · Collagen Medical, Llc · R44 · FY2017 · CA
Targeted Intraceptors for Macular Degeneration
$1,002,479Randon Michael Burr · Iveena Delivery Systems, Inc. · R44 · FY2020 · EY
Development of Anti-necrosis Drug for Acute Brain Injury
$1,002,243Junying Yuan · Harvard Medical School · U01 · FY2007 · NS
Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices
$1,002,182Glenn Brunner · N8 Medical, Inc. · R44 · FY2022 · HL
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$1,001,898Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2019 · CA
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
$1,001,404Gal Shafirstein · Pop Biotechnologies, Inc · R42 · FY2022 · CA
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
$1,001,024Thomas Edward Smithgall · Fox Chase Chemical Diversity Center, Inc · R42 · FY2016 · GM
A Novel Peptide Therapeutic for Obesity
$1,000,985Neil A Fanger · Virtici, Llc · R44 · FY2017 · DK
Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis
$1,000,618James Craig Hartman · Mdi Therapeutics, Inc. · R44 · FY2022 · HL
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2013 · AI